|Bid||94.17 x 1100|
|Ask||98.76 x 800|
|Day's Range||95.87 - 100.66|
|52 Week Range||39.55 - 127.42|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 11, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||128.50|
A top IPO and big dividend payer are among five market hot stocks big mutual funds are starting positions or increasing their stakes in.
IRVINE, Calif., April 29, 2021 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (“Inari”), a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, announced today that its management team will present at the 2021 Bank of America Healthcare Conference on Thursday, May 13, 2021 at 8:45 a.m. Eastern Time. About Inari Medical, Inc.Inari Medical, Inc. is a commercial-stage medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases. Inari has developed two minimally-invasive, novel catheter-based mechanical thrombectomy devices that are designed to remove large clots from large vessels and eliminate the need for thrombolytic drugs. The company purpose-built its products for the specific characteristics of the venous system and the treatment of the two distinct manifestations of venous thromboembolism, or VTE: deep vein thrombosis and pulmonary embolism. The ClotTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of deep vein thrombosis. The FlowTriever system is 510(k)-cleared by the FDA and CE Mark approved for the treatment of pulmonary embolism and clot in transit in the right atrium. Investor Contact:Westwicke PartnersCaroline CornerPhone +1-415-202-5678 email@example.com
Small-cap stocks are public companies that have market capitalizations ranging from $300 million to $2 billion. Since the share prices of these companies can be very volatile, some companies in the small-cap universe or in small-cap indexes can have market caps significantly higher than this range at any particular time. Small-cap stocks, as represented by the Russell 2000 Index, have significantly outperformed the broader market, providing investors with a total return of 88.5% compared to the Russell 1000's total return of 54.4% over the past 12 months.